Immix Biopharma Inc

詳細情報 Immix Biopharma Inc 企業名

Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the application of chimeric antigen receptor cell therapy (CAR- T) in light chain (AL) Amyloidosis and autoimmune disease. The Company's lead cell therapy asset is CAR-T NXC-201 for autoimmune disease, relapsed/refractory AL Amyloidosis, and relapsed/refractory multiple myeloma, which is being evaluated in its ongoing Phase Ib/IIa NEXICART-1 (NCT04720313) clinical trial. Its tissue specific therapeutic IMX-110 is in clinical trials as a monotherapy, and in combination with tislelizumab (BeiGene anti-PD-1 - IMMINENT-01 NCT05840835) for advanced solid tumors, such as relapsed/refractory colorectal cancer (CRC). IMX-110 in Phase Ib/IIa clinical trials, is a Tissue-Specific Therapeutic with TME Normalization, a technology that the Company is developing initially for mCRC and Soft Tissue Sarcoma (STS).

企業情報

企業コードIMMX

会社名Immix Biopharma Inc

上場日Dec 16, 2021

最高経営責任者「CEO」Dr. Ilya Rachman, M.D., Ph.D.

従業員数18

証券種類Ordinary Share

決算期末Dec 16

本社所在地11400 West Olympic Blvd.

都市LOS ANGELES

証券取引所NASDAQ Capital Market Consolidated

国United States of America

郵便番号90064

電話番号18889581084

ウェブサイトhttps://immixbio.com/

企業コードIMMX

上場日Dec 16, 2021

最高経営責任者「CEO」Dr. Ilya Rachman, M.D., Ph.D.

役員一覧

会社名

会社名/ポジション

ポジション

株式保有

変動額

Mr. Jason Hsu, Ph.D.

Independent Director

4.86M

--

Ms. Helen C. Adams, CPA

Lead Independent Director

174.75K

-0.13%

Dr. Magda Marquet, Ph.D.

Independent Director

173.19K

+161.79%

Mr. Gabriel Morris

Chief Financial Officer, Director

--

Dr. Graham Ross

Acting Chief Medical Officer, Head - Clinical Development

--

Ms. Jane M. Buchan, Ph.D.

Independent Director

--

Dr. Ilya Rachman, M.D., Ph.D.

Chairman of the Board, Chief Executive Officer

--

Mr. Carey Ng, Ph.D.

Independent Director

--

Dr. Vladimir Torchilin, Ph.D.

Scientific Co-Founder

--

Dr. Nancy T. Chang, Ph.D.

Director

--

詳細を見る

会社名

会社名/ポジション

ポジション

株式保有

変動額

Mr. Jason Hsu, Ph.D.

Independent Director

4.86M

--

Ms. Helen C. Adams, CPA

Lead Independent Director

174.75K

-0.13%

Dr. Magda Marquet, Ph.D.

Independent Director

173.19K

+161.79%

Mr. Gabriel Morris

Chief Financial Officer, Director

--

Dr. Graham Ross

Acting Chief Medical Officer, Head - Clinical Development

--

Ms. Jane M. Buchan, Ph.D.

Independent Director

--

収益内訳

データなし

データなし

事業別

地域別

データなし

株主

更新時刻: Sat, Aug 16

株主統計

種類

株主統計

比率

Hsu (Jason)

14.87%

GKCC, LLC

9.92%

Rachman (Ilya M)

3.49%

Ng (Carey)

3.20%

Bleichroeder LP

2.60%

他の

65.91%

株主統計

比率

Hsu (Jason)

14.87%

GKCC, LLC

9.92%

Rachman (Ilya M)

3.49%

Ng (Carey)

3.20%

Bleichroeder LP

2.60%

他の

65.91%

種類

株主統計

比率

Individual Investor

24.49%

Corporation

9.92%

Investment Advisor

5.98%

Investment Advisor/Hedge Fund

2.33%

Research Firm

0.15%

他の

57.13%

機関投資家保有株

更新時刻: Tue, Jul 1

報告期間

機関投資家数

保有株式数

比率

変動額

2025Q2

65

14.67M

52.67%

-1.12M

2025Q1

66

14.50M

53.34%

-1.02M

2024Q4

67

14.42M

52.43%

-1.29M

2024Q3

66

15.60M

56.77%

-243.92K

2024Q2

66

15.89M

59.32%

-308.72K

2024Q1

64

15.43M

77.52%

+5.90M

2023Q4

57

11.10M

62.12%

+3.00M

2023Q3

52

12.47M

73.23%

+2.63M

2023Q2

46

9.35M

66.71%

-203.85K

2023Q1

40

9.11M

65.58%

-364.69K

詳細を見る

株主動向

会社名

保有株式数

比率

変動額

変動率

日付

Hsu (Jason)

4.86M

17.45%

--

Apr 22, 2025

GKCC, LLC

3.24M

11.64%

--

Apr 22, 2025

Rachman (Ilya M)

1.14M

4.09%

+2.18K

+0.19%

Jun 18, 2025

Ng (Carey)

1.05M

3.75%

--

Apr 22, 2025

Bleichroeder LP

850.00K

3.05%

--

Mar 31, 2025

The Vanguard Group, Inc.

698.54K

2.51%

--

Mar 31, 2025

Morris (Gabriel S)

583.04K

2.09%

+2.23K

+0.38%

Jun 18, 2025

Lynwood Capital Management Inc.

405.00K

1.45%

+405.00K

--

Mar 31, 2024

Adams (Helen C)

174.75K

0.63%

-227.00

-0.13%

Apr 22, 2025

Marquet (Magda)

173.19K

0.62%

+107.03K

+161.79%

Apr 22, 2025

詳細を見る

2.190USD

Immix Biopharma Inc

2.190

概要

企業名

金融

分析